About
Dr.Farah Deeba has done Ph.D. in Pharamcology, M.Pharm(Pharmacology) and B.Pharm from Jamia Hamdard NIRF no.1(2022) . PGDDRA from Jamia Hamdard.
Experience
- Research experience 7 years, Teaching 2.5 Years
Qualification
- PhD (Pharmacology)
Award & Recognition
- Awarded for best impact factor in Drug Discovery Today by Jamia Hamdard on National Science Day 2022.
- Awarded for best scholar Project by SGT university 2023.
Research
- Evaluation of Hepatoprotective and Antioxidant Activity of Unani Formulation (SAFI) Dated: 31-05- 2019, Indian. Journal of. Unani Medicine., Vol.12, Iss.1, PP 27- 38, January- June 2019.
- Insect Venom peptides as potent inhibitors of Escherichia coli ATP synthase. Journal: International Journal Biological of Macromolecules. IF: 6.953
- Targeting ECS in diabesity: Fact or Fiction. Journal: Drug Discovery Today. IF: 8.369.
- Synthesis, molecular docking, and pharmacological evaluation of 5-(4- (2-(5- ethylpyridine-2-yl) ethoxy) benzyl)-3-(phenylsulfonyl) thiazolidine-2, 4-dione against HFD-induced diabesity via interaction with the CB1 receptor Farah Deeba 1, Mohammad Shahar Yar 2, Mohammad Rafi Haidar.IF:3.51.
- Versatile Therapeutic Potential of Gabapentin Mohit Yadav, Farah Deeba2, Silky Sethi.Journal: Journal of Pharmaceutical Negative Results.
Certifications
- IPGA member, Association of young Pharma Professionals
Area of Interest
- Endocannabinoid System,Diabesity,CB1 antagonism